文献速递重症综合管理与镇静镇痛

脓毒症大鼠血清补体及促炎细胞因子的研究

[The study of serum complements and proinflammatory cytokines in sepsis rats].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2017-01-01
一句话结论脓毒症大鼠模型显示补体C5、C5a及IL-1β在24小时显著升高,HMGB1呈时间依赖性上升,提示补体系统可能通过促炎细胞因子参与脓毒症病理机制。

该研究将120只健康雄性Wistar大鼠随机分为正常对照组(n=15)、假手术组(n=15)和脓毒症组(盲肠结扎穿刺术,n=90),脓毒症组分别于造模后24、48、72小时处死,用酶联免疫吸附法检测血清补体C5、C5a及细胞因子TNF-α、IL-1、IL-6、HMGB1、MIF。结果显示脓毒症组24小时C5、C5a、IL-1β显著高于正常对照组和假手术组(均P<0.05),随后下降,但48、72小时C5仍高于正常对照组(均P<0.05);TNF-α在48、72小时低于正常对照组和假手术组(均P<0.05);HMGB1呈时间依赖性升高,72小时显著高于两对照组(均P<0.05);MIF和IL-6各时间点组间无显著差异。作者认为补体系统通过释放促炎细胞因子和炎症介质导致失控炎症反应和免疫功能障碍,可能是脓毒症病理机制之一。

要点

  • 脓毒症大鼠造模后24小时血清C5、C5a、IL-1β显著高于正常对照组和假手术组(均P<0.05)。
  • 脓毒症组血清C5在48小时和72小时仍高于正常对照组(均P<0.05)。
  • 脓毒症组血清HMGB1呈时间依赖性升高,72小时显著高于正常对照组和假手术组(均P<0.05)。
  • 脓毒症组TNF-α在48小时和72小时低于正常对照组和假手术组(均P<0.05)。
  • MIF和IL-6在各时间点组间无显著差异。

适用人群与场景

  • 健康雄性Wistar大鼠,共120只,随机分为正常对照组(n=15)、假手术组(n=15)和脓毒症组(n=90)。
  • 脓毒症组采用盲肠结扎穿刺术(CLP)造模,分别于造模后24、48、72小时处死检测。

研究设计与关键结果

  • 研究类型:动物实验;样本量:120只健康雄性Wistar大鼠;分组:正常对照组(n=15)、假手术组(n=15)、脓毒症组(CLP,n=90)。
  • 脓毒症组24小时C5(ng/L)1.60±0.19 vs 正常对照组1.04±0.20、假手术组1.09±0.09,均P<0.05。
  • 脓毒症组24小时C5a(ng/L)0.20±0.02 vs 正常对照组0.18±0.01、假手术组0.18±0.02,均P<0.05。
  • 脓毒症组24小时IL-1β(ng/L)700.20±111.41 vs 正常对照组475.87±108.96、假手术组592.29±121.57,均P<0.05。
  • 脓毒症组48小时和72小时C5(ng/L)分别为1.17±0.24、1.27±0.24,均高于正常对照组1.04±0.20(均P<0.05)。
  • 脓毒症组48小时和72小时TNF-α(ng/L)分别为51.33±1.96、51.06±1.64,低于正常对照组59.53±3.06和假手术组57.91±2.72(均P<0.05)。
  • 脓毒症组72小时HMGB1(ng/L)472.21±20.94 vs 正常对照组406.00±43.16、假手术组404.41±35.39,均P<0.05;HMGB1在脓毒症组呈时间依赖性升高。
  • MIF和IL-6水平在各时间点组间无显著差异。

证据类型、等级与局限

  • 证据类型:动物实验(大鼠CLP脓毒症模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为补体系统通过释放促炎细胞因子和炎症介质导致失控炎症反应和免疫功能障碍,可能是脓毒症病理机制之一。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To observe the changes of serum complements and proinflammatory cytokines in rats with sepsis, and to explore the possible mechanism.

METHODS: 120 healthy male Wistar rats were randomly divided into three groups: normal control group (n = 15), sham operation group (n = 15) and sepsis group [cecum ligation and puncture (CLP) operation, n = 90]. The sepsis rats were sacrificed on 24, 48 and 72 hours after modeling. The level of serum complements (C5, C5a) and cytokines tumor necrosis factor-α (TNF-α), interleukin (IL-1, IL-6), high mobility group box 1 (HMGB1), macrophage migration inhibitory factor (MIF) were detected by enzyme linked immunosorbent assay (ELISA).

RESULTS: Compared with normal control group and sham operation group, the levels of serum complements C5, C5a and IL-1β were significantly increased at 24 hours after CLP in sepsis group [C5 (ng/L): 1.60±0.19 vs. 1.04±0.20, 1.09±0.09; C5a (ng/L): 0.20±0.02 vs. 0.18±0.01, 0.18±0.02; IL-1β (ng/L): 700.20±111.41 vs. 475.87±108.96, 592.29±121.57; all P < 0.05]; then the levels of C5, C5a and IL-1β declined, the level of serum C5 were also higher than normal control group at 48 hours and 72 hours after CLP (ng/L: 1.17±0.24, 1.27±0.24 vs. 1.04±0.20, both P < 0.05). In sepsis group the level of serum TNF-α (ng/L: 51.33±1.96, 51.06±1.64) was lower than that in normal control group (59.53±3.06) and sham operation group (57.91±2.72) at 48 hours and 72 hours (all P < 0.05). There was a time dependent rise of serum HMGB1 in sepsis group, which level was much higher than that in normal control group and sham operation group at 72 hours after CLP (ng/L: 472.21±20.94 vs. 406.00±43.16, 404.41±35.39, both P < 0.05). There were no significant differences of MIF, and IL-6 level between groups at each time points.

CONCLUSIONS: Complement system led to uncontrolled inflammatory response and immune dysfunction through the release of proinflammatory cytokines and inflammatory mediators, which maybe one of the important mechanism of the pathology of sepsis.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Sun P, Wang D, Zhou C, et al. [The study of serum complements and proinflammatory cytokines in sepsis rats]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017. PMID: 28420473. doi:10.3760/cma.j.issn.2095-4352.2017.04.015

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。